SCHEMBL2470146

SCHEMBL2470146

CCc1ccc(CCNC(=O)C2(Cc3ccccc3)CCN(C(=O)c3ccc(C)nc3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
LMNA P02545 2/20 0.47
PKLR P30613 1/20 0.43
OPRM1 P35372 1/20 0.43
MAPT P10636 3/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KMT2A Q03164 5/20 0.42
TP53 P04637 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GRM5 P41594 1/20 0.41
P2RY12 Q9H244 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 3/20 0.41
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
NAMPT P43490 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468026 0.88 CHRM2 (0.52) ALDH1A1LMNAPKLRMAPTNPC1
SCHEMBL2470282 0.88 ALDH1A1 (0.48) ALDH1A1LMNAPKLRMAPTNPC1
SCHEMBL2471483 0.88 ALDH1A1 (0.55) ALDH1A1RAB9AKMT2AMEN1POLB
SCHEMBL2465757 0.86 CYP3A4 (0.49) ALDH1A1PKLRTSHRRAB9AKMT2A
SCHEMBL2471026 0.85 EPHX1 (0.50) ALDH1A1LMNAPKLRMAPTSMN1; SMN2
SCHEMBL2472974 0.85 KMT2A (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL2467860 0.84 KMT2A (0.55) ALDH1A1LMNAPKLRMAPTNPC1
SCHEMBL2468511 0.82 L3MBTL1 (0.45) ALDH1A1LMNAPKLRKMT2AKDM4E
SCHEMBL2699832 0.82 ALDH1A1 (0.48) ALDH1A1LMNAPKLRNPC1RAB9A
SCHEMBL2471222 0.82 CYP2D6 (0.53) ALDH1A1LMNANPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 ALDH1A1 3941/4885LMNA 1070/4885PKLR 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.